Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: Obinutuzumab
Drug: Fludarabine
Drug: Venetoclax
Drug: Cyclophosphamide
Drug: Rituximab
Drug: Bendamustine

First Posted Date: 2020-02-26

Last Posted Date: 2024-10-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 166

Registration Number: NCT04285567

Locations: 🇫🇷
CHU de Caen, Institut d'Hématologie de Basse-Normandie, Caen, France
🇫🇷
Hopital Robert Debre; Hematologie Clinique, Reims, France
🇺🇸
Oncology & Hematolgy Associates of SW Va Inc. - Roanoke, Roanoke, Virginia, United States

and more 45 locations

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Phase 2

Withdrawn

Conditions: Hematologic Malignancy
Hematologic Diseases
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia

Interventions: Device: CliniMACS
Procedure: Bone Marrow Transplant
Drug: Hyperfractionated Total Body Irradiation
Drug: Busulfan
Drug: Thiotepa
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2020-02-24

Last Posted Date: 2022-09-27

Lead Sponsor: Baptist Health South Florida

Registration Number: NCT04282174

Locations: 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Phase 2

Active, not recruiting

Conditions: Hodgkin Lymphoma, Adult
Hodgkin Disease Recurrent
Hodgkin Disease Refractory
Hodgkin Disease, Pediatric

Interventions: Drug: CD30.CAR-T
Drug: Fludarabine
Drug: Bendamustine

First Posted Date: 2020-02-13

Last Posted Date: 2023-04-05

Lead Sponsor: Tessa Therapeutics

Target Recruit Count: 97

Registration Number: NCT04268706

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

Early Phase 1

Conditions: B-cell Lymphoma
B-cell Acute Lymphoblastic Leukemia

Interventions: Biological: anti-CD19 UCAR-T cells
Drug: Fludarabine
Drug: Cytoxan
Drug: Melphalan

First Posted Date: 2020-02-11

Last Posted Date: 2020-02-11

Lead Sponsor: Xinqiao Hospital of Chongqing

Target Recruit Count: 30

Registration Number: NCT04264039

Locations: 🇨🇳
Department of Hematology, Xinqiao Hospital, ChongQing, Chongqing, China

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Early Phase 1

Conditions: T-cell Leukemia
T-cell Lymphoma

Interventions: Biological: CD7 UCAR-T cells
Drug: Fludarabine
Drug: Cytoxan
Drug: Melphalan

First Posted Date: 2020-02-11

Last Posted Date: 2021-06-28

Lead Sponsor: Xinqiao Hospital of Chongqing

Target Recruit Count: 30

Registration Number: NCT04264078

Locations: 🇨🇳
Department of Hematology, Xinqiao Hospital, ChongQing, Chongqing, China

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

Phase 2

Recruiting

Conditions: Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
High Risk Myelodysplastic Syndrome

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate
Biological: Granulocyte Colony-Stimulating Factor
Procedure: Hematopoietic Cell Transplantation
Procedure: Intensity-Modulated Radiation Therapy
Drug: Mycophenolate Mofetil
Drug: Tacrolimus

First Posted Date: 2020-02-10

Last Posted Date: 2024-03-06

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 70

Registration Number: NCT04262843

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Recurrent Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome
Recurrent Myeloproliferative Neoplasm

Interventions: Drug: Cytarabine
Biological: Filgrastim
Drug: Fludarabine
Drug: Fludarabine Phosphate
Drug: Ivosidenib

First Posted Date: 2020-01-31

Last Posted Date: 2023-05-15

Lead Sponsor: Northwestern University

Target Recruit Count: 25

Registration Number: NCT04250051

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Phase 1

Terminated

Conditions: Lymphoma, B-Cell
Chronic Lymphocytic Leukemia

Interventions: Drug: FT596
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine
Drug: Rituximab
Drug: Obinutuzumab

First Posted Date: 2020-01-29

Last Posted Date: 2023-10-26

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 98

Registration Number: NCT04245722

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 6 locations

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Phase 2

Recruiting

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: JCAR017

First Posted Date: 2020-01-29

Last Posted Date: 2024-12-10

Lead Sponsor: Celgene

Target Recruit Count: 276

Registration Number: NCT04245839

Locations: 🇺🇸
University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Local Institution - 111, Santa Monica, California, United States
🇺🇸
University Of Colorado Cancer Center, Aurora, Colorado, United States

and more 54 locations

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)

Interventions: Drug: gilteritinib
Drug: fludarabine
Drug: cytarabine
Drug: granulocyte colony-stimulating factor (G-CSF)

First Posted Date: 2020-01-27

Last Posted Date: 2024-12-19

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 97

Registration Number: NCT04240002

Locations: 🇩🇪
Site DE49001, Halle (Saale), Sachsen-Anhalt, Germany
🇮🇹
SIte IT39001, Roma, Italy
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 22 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy